Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baricitinib + methotrexate
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of baricitinib, an oral selective JAK1/JAK2 inhibitor, and methotrexate, a conventional synthetic disease-modifying antirheumatic drug (csDMARD). This combination is primarily used for treating moderate to severe rheumatoid arthritis in patients who have had inadequate response to previous therapies. The combination provides superior efficacy compared to either agent alone, with more rapid and greater improvements in disease activity, pain relief, and physical function.
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)DHFR (Dihydrofolate reductase)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on baricitinib + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baricitinib + methotrexate.